1-2 of 2
Keywords: Empagliflozin
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Clin Sci (Lond) (2019) 133 (15): 1705–1720.
Published: 02 August 2019
... as an important cause of heart failure. EMPA-REG OUTCOME trial has reported that empagliflozin, the sodium-glucose cotransporter 2 inhibitor, exerts cardiovascular benefits on diabetic population. However, the mechanism by which empagliflozin alleviates DCM still remains unclear. In the current study, we...
Includes: Supplementary data